| Serial Number | 90301418 |
| Word Mark | ADC THERAPEUTICS |
| Filing Date | Thursday, November 5, 2020 |
| Status | 733 - FOURTH EXTENSION - GRANTED |
| Status Date | Tuesday, August 6, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 14, 2022 |
| Goods and Services | Pharmaceutical preparations for use in the prevention of cancer and tumors; pharmaceutical preparations for use in the prevention of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of infectious, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations and biological preparations in the nature of pharmaceutical and biological preparations for the treatment of infectious, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations and substances for conditioning patients to receive therapies for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; diagnostic agents, preparations, and substances for medical purposes; reagents for medical use; diagnostic kits comprised of medical diagnostic reagents and assays to test tissue for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic kits comprised of medical diagnostic reagents and assays to test bodily fluids for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; medical diagnostic assays for testing body fluids; medical diagnostic assays for testing body tissue; diagnostic kits comprised of medical diagnostic assays to test for cell expressions for use in identifying pharmaceutical preparations and therapies for treating medical diseases, disorders, and conditions in humans |
| NOT AVAILABLE | "THERAPEUTICS" |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 6, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | ADC Therapeutics SA |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Epalinges 1066 CH |
| Party Name | ADC Therapeutics SA |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Epalinges 1066 CH |
| Event Date | Event Description |
| Monday, November 9, 2020 | NEW APPLICATION ENTERED |
| Wednesday, January 6, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, April 12, 2021 | ASSIGNED TO EXAMINER |
| Tuesday, April 13, 2021 | NON-FINAL ACTION WRITTEN |
| Tuesday, April 13, 2021 | NON-FINAL ACTION E-MAILED |
| Tuesday, April 13, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, October 12, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, October 12, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, October 13, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, November 12, 2021 | FINAL REFUSAL WRITTEN |
| Friday, November 12, 2021 | FINAL REFUSAL E-MAILED |
| Friday, November 12, 2021 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, April 6, 2022 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Wednesday, April 6, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 6, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, April 26, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, May 10, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, May 25, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, June 14, 2022 | PUBLISHED FOR OPPOSITION |
| Tuesday, June 14, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, August 9, 2022 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Thursday, February 9, 2023 | SOU TEAS EXTENSION RECEIVED |
| Thursday, February 9, 2023 | SOU EXTENSION 1 FILED |
| Thursday, February 9, 2023 | SOU EXTENSION 1 GRANTED |
| Saturday, February 11, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, August 9, 2023 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, August 9, 2023 | SOU EXTENSION 2 FILED |
| Wednesday, August 9, 2023 | SOU EXTENSION 2 GRANTED |
| Friday, August 11, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, February 8, 2024 | SOU TEAS EXTENSION RECEIVED |
| Thursday, February 8, 2024 | TEAS REQUEST TO DIVIDE RECEIVED |
| Thursday, February 8, 2024 | SOU EXTENSION 3 FILED |
| Monday, February 26, 2024 | DIVISIONAL REQUEST RECEIVED |
| Tuesday, February 27, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Friday, March 8, 2024 | DIVISIONAL PROCESSING COMPLETE |
| Friday, March 8, 2024 | SOU EXTENSION 3 GRANTED |
| Saturday, March 9, 2024 | CORRECTED NOA E-MAILED |
| Saturday, March 9, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, August 6, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, August 6, 2024 | SOU EXTENSION 4 GRANTED |
| Tuesday, August 6, 2024 | SOU EXTENSION 4 FILED |
| Tuesday, August 6, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |